●Feedback regulation of lymphocyte signalling. Reth, M. & Brummer, T. Nature Reviews Immunology April (2004)

●Turning the key on p53. Lane, D. P. & Fischer, P. M. Nature 26 February (2004) Small-molecule drugs that can selectively reactivate p53 in tumour cells by blocking binding of the p53 inhibitor MDM2 are discussed in this News and Views article.

●Fragile fugue: p53 in aging, cancer and IGF signaling. Campisi, J. Nature Medicine March (2004) This News and Views article describes a new study that directly links the tumour-suppressor p53 to the IGF1 signalling pathway.

●Chemogenomics: an emerging strategy for rapid target and drug discovery. Bredel, M. & Jacoby, E. Nature Reviews Genetics April (2004)

●Delivering on the promise: HPV vaccines and cervical cancer. Schiller, J. T. & Davies, P. Nature Reviews Microbiology April (2004)

●Cancer without disease. Folkman, J. & Kalluri, R. Nature 26 February (2004) Many people have tiny tumours, but fail to clinnically relevant cancer. So how do in situ carcinomas grow and become lethal? This article explores the role of angiogenesis in the progression of cancer.

●Case of mistaken identity. Bassing, C. H. & Alt, F. W. Nature 4 March (2004) The RAG protein complex cuts double-stranded DNA during V(D)J recombination — a specialized form of DNA recombination in T and B cells that generates antigen receptors. This News and Views article explains how RAG causes single-stranded breaks near the BCL2 proto-oncogene that cause BCL2 to recombine with antigen-receptor loci in follicular B-cell lymphoma.

●Endothelial cell–cell junctions: happy together. Dejana, E. Nature Reviews Molecular Cell Biology April (2004)